Profile data is unavailable for this security.
About the company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
- Revenue in USD (TTM)16.10m
- Net income in USD-198.97m
- Incorporated2012
- Employees221.00
- LocationUniqure NVPaasheuvelweg 25aAMSTERDAM 1105 BPNetherlandsNLD
- Phone+31 202406000
- Fax+31 202406020
- Websitehttps://www.uniqure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neumora Therapeutics Inc | 0.00 | -236.30m | 504.27m | 95.00 | -- | 3.75 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 515.07m | 41.00 | -- | 2.28 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 516.02m | 72.00 | -- | 3.21 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 521.13m | 202.00 | -- | 1.88 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 524.14m | 55.00 | -- | 1.50 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 559.56m | 30.00 | -- | 3.90 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Uniqure NV | 16.10m | -198.97m | 562.49m | 221.00 | -- | 2.83 | -- | 34.94 | -3.48 | -3.48 | 0.2814 | 3.19 | 0.0233 | -- | 2.74 | 72,841.63 | -28.81 | -15.62 | -31.13 | -16.94 | 89.53 | 91.01 | -1,236.00 | -78.92 | -- | -9.79 | 0.7244 | -- | -40.64 | -15.57 | 16.94 | -- | -45.91 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 568.57m | 226.00 | -- | 1.79 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 569.64m | 55.00 | -- | 2.85 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 570.78m | 65.00 | -- | 3.39 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 588.94m | 138.00 | -- | 1.59 | -- | 547.85 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 592.05m | 479.00 | -- | 2.71 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 597.32m | 5.00 | -- | 117.39 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 598.05m | 409.00 | -- | -- | -- | 21.81 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| Ocugen Inc | 5.37m | -64.02m | 609.87m | 95.00 | -- | 164.43 | -- | 113.57 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
Data as of Mar 04 2026. Currency figures normalised to Uniqure NV's reporting currency: US Dollar USD
48.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 6.15m | 9.87% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 5.54m | 8.89% |
| RTW Investments LPas of 31 Dec 2025 | 3.71m | 5.96% |
| abrdn, Inc.as of 31 Dec 2025 | 3.68m | 5.91% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.23m | 5.19% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 2.45m | 3.93% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.56m | 2.51% |
| Two Sigma Investments LPas of 31 Dec 2025 | 1.45m | 2.33% |
| Jennison Associates LLCas of 31 Dec 2025 | 1.37m | 2.20% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 1.22m | 1.96% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
